Compare Organon & Co. Common Stock (OGN) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Global X SuperDividend ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Global X SuperDividend ETF trades at $23.65 (market cap $1.18B). The key difference: Organon & Co. Common Stock is far larger — about 3.1× Global X SuperDividend ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Global X SuperDividend ETF for 49 Days on average.
| OGN | SDIV | |
|---|---|---|
Market Cap | $3.62B | $1.18B |
Volume | 2,892,999 | 591,359 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $26.34 |
52-Week Low | $5.70 | $23.16 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SDIV trades at $23.88, down 0.21% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, with a 66% price decline since inception noted by Seeking Alpha on September 11, 2026. Recent institutional buying includes Ameritas Advisory increasing its position by 92.6% in Q2 2026 per SEC filings.
High dividend yield attracts income investors but comes with significant capital depreciation risks. Media coverage highlights sustainability concerns, while technical indicators suggest near-term consolidation. The outlook remains cautious due to persistent underperformance versus benchmarks and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
